A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds

Mol Biol Rep. 2021 Jan;48(1):787-805. doi: 10.1007/s11033-020-06084-0. Epub 2021 Jan 3.

Abstract

Advanced glycation end products (AGEs) are naturally occurring biomolecules formed by interaction of reducing sugars with biomolecules such as protein and lipids etc., Long term high blood sugar level and glycation accelerate the formation of AGEs. Unchecked continuous formation and accumulation of AGEs are potential risks for pathogenesis of various chronic diseases. Current mode of antidiabetic therapy is based on synthetic drugs that are often linked with severe adverse effects. Polyphenolic compounds derived from plants are supposed to inhibit glycation and formation of AGEs at multiple levels. Some polyphenolic compounds regulate the blood glucose metabolism by amplification of cell insulin resistance and activation of insulin like growth factor binding protein signaling pathway. Their antioxidant nature and metal chelating activity, ability to trap intermediate dicarbonyl compounds could be possible mechanisms against glycation and AGEs formation and hence, against AGEs induced health complications. Although, few species of polyphenolic compounds are being used in in vitro trials and their in vivo study is still in progress, increasing the area of research in this field may produce a fruitful approach in management of overall diabetic complications.

Keywords: AGEs; AGEs inhibitors; Anti-AGEs strategies; Antiglycating mechanism; Polyphenolic compounds.

Publication types

  • Review

MeSH terms

  • Antioxidants / therapeutic use*
  • Blood Glucose / metabolism
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / genetics
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / pathology
  • Gene Expression Regulation
  • Glycation End Products, Advanced / antagonists & inhibitors*
  • Glycation End Products, Advanced / genetics
  • Glycation End Products, Advanced / metabolism
  • Glycosylation
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Resistance
  • Insulin-Like Growth Factor Binding Protein 1 / genetics
  • Insulin-Like Growth Factor Binding Protein 1 / metabolism
  • Obesity / drug therapy*
  • Obesity / genetics
  • Obesity / metabolism
  • Obesity / pathology
  • Phytochemicals / therapeutic use*
  • Polyphenols / therapeutic use*
  • Signal Transduction

Substances

  • Antioxidants
  • Blood Glucose
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • IGFBP1 protein, human
  • Insulin-Like Growth Factor Binding Protein 1
  • Phytochemicals
  • Polyphenols